News Releases

Latest News Releases

Sep 10, 2026
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Download
Facebook Twitter LinkedIn Email this page
Sep 02, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
Facebook Twitter LinkedIn Email this page
Aug 05, 2026
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Download
Facebook Twitter LinkedIn Email this page
Jun 02, 2026
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Download
Facebook Twitter LinkedIn Email this page
Jun 01, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
Facebook Twitter LinkedIn Email this page
May 07, 2026
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Download
Facebook Twitter LinkedIn Email this page
May 07, 2026
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Download
Facebook Twitter LinkedIn Email this page
May 06, 2026
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Download
Facebook Twitter LinkedIn Email this page
Mar 02, 2026
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download
Facebook Twitter LinkedIn Email this page
Feb 26, 2026
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Download
Facebook Twitter LinkedIn Email this page

Quick access to common resources

Frequently Asked Questions Frequent questions about owning stock in Entrada. SEC Filings View current and past SEC filings in various easy-to-access file formats. Events & Presentation View our latest events and presentation.